ArticleJID innovations : skin science from molecules to population health2026
Global skin cancer burden and United States mortality trends in younger adults (Aged 20-44 Years): An analysis of the Global Burden of Disease Study 2021 and CDC WONDER Databases.
Article in JID innovations : skin science from molecules to population health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin cancer is a growing public health concern, yet patterns in younger adults remain inadequately described. We quantified the global incidence, mortality, disability-adjusted life years, and age-standardized rates of melanoma and nonmelanoma skin cancer in adults aged 20-44 years using Global Burden of Disease 2021 estimates and assessed United States melanoma mortality in those aged 25-44 years from 1999 to 2023 using national vital statistics. From 1990 to 2021, age-standardized melanoma incidence declined, whereas nonmelanoma skin cancer cases rose from 142,018 to 292,052, with an increasing age-standardized incidence of basal cell carcinoma. The burden was greatest in countries with higher sociodemographic development and peaked at ages 40-44 years; women experienced a higher incidence, but men had higher mortality. In the United States, melanoma mortality decreased from 0.99 to 0.47 deaths per 100,000 between 1999 and 2023, representing an average annual reduction of 3.56%. Projections suggest continued declines in melanoma but sustained increases in nonmelanoma skin cancer. These findings indicate a growing and uneven skin cancer burden in young adults, supporting targeted prevention and earlier detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.